COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
M Gulyas, JSM Mattsson, A Lindgren, L Ek… - Acta …, 2018 - Taylor & Francis
Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …
[HTML][HTML] COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
M Gulyas, JSM Mattsson, A Lindgren, L Ek, K Lamberg… - 2016 - diva-portal.org
Methods: In the multicenter phase III trial, 316 patients with advanced NSCLC were
randomized to receive celecoxib (400 mg bid) or placebo up to one year in addition to a two …
randomized to receive celecoxib (400 mg bid) or placebo up to one year in addition to a two …
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
M Gulyas, JSM Mattsson, A Lindgren, L Ek… - Acta …, 2018 - portal.research.lu.se
Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in several
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
M Gulyas, JSM Mattsson, A Lindgren… - Acta oncologica …, 2018 - pubmed.ncbi.nlm.nih.gov
Aim Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in several
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
M Gulyas, JSM Mattsson, A Lindgren, L Ek… - Acta …, 2018 - actaorthop.org
Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in several
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
M Gulyas, JSM Mattsson, A Lindgren, L Ek… - Acta Oncologica …, 2017 - europepmc.org
Aim Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in several
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
[PDF][PDF] COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
ACTA ONCOLOGICA, 2018 - academia.edu
ABSTRACT Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option
in several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials …
in several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials …
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
M Gulyas, JS Margareta Mattsson… - Acta …, 2018 - search.ebscohost.com
Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
M Gulyas, JSM Mattsson, A Lindgren, L Ek… - Acta …, 2018 - actaorthop.org
Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in several
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
M Gulyas, JSM Mattsson, A Lindgren, L Ek… - Acta …, 2018 - diva-portal.org
Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in several
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …
cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to …